A preliminary benefit-risk assessment of varenicline in smoking cessation.


Varenicline is a recently developed medication for smoking cessation, which has been available on prescription since 2006. It is a selective nicotinic acetylcholine receptor partial agonist, and is designed to reduce withdrawal symptoms and to lessen the rewards of continued smoking. Our objective in this article is to assess the efficacy of varenicline as… (More)
DOI: 10.2165/00002018-200932020-00005